Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates [Yahoo! Finance]
Neurogene Inc. (NGNE)
Company Research
Source: Yahoo! Finance
Continues to expect to share additional interim clinical data from NGN-401 Phase 1/2 trial in the second half of 2025 Received PRIME designation for NGN-401 from the European Medicines Agency Cash runway into the second half of 2027 NEW YORK, March 24, 2025 BUSINESS WIRE )--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced fourth quarter and full year 2024 financial results and highlighted recent corporate updates. "We believe 2024 was a year of significant progress for our NGN-401 Phase 1/2 trial in Rett syndrome, as we reported encouraging interim efficacy data and NGN-401 was generally well-toler
Read more
Impact Snapshot
Event Time:
NGNE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NGNE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NGNE alerts
High impacting Neurogene Inc. news events
Weekly update
A roundup of the hottest topics
NGNE
News
- Neurogene Inc. (NASDAQ: NGNE) had its "outperform" rating re-affirmed by analysts at William Blair.MarketBeat
- Neurogene Inc. (NASDAQ: NGNE) had its price target lowered by analysts at HC Wainwright from $55.00 to $50.00. They now have a "buy" rating on the stock.MarketBeat
- Neurogene Inc. (NGNE) Stock [Seeking Alpha]Seeking Alpha
- Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent UpdatesBusiness Wire
- MAAST DIGITAL Unveils AI-Powered ERMA Evaluate™: A Revolutionary Platform Set to Transform the Traditional Medical, Legal and Regulatory Review Process for Life Science Companies [Yahoo! Finance]Yahoo! Finance
NGNE
Earnings
- 11/18/24 - Beat
NGNE
Sec Filings
- 3/28/25 - Form 4
- 3/28/25 - Form 4
- 3/28/25 - Form 4
- NGNE's page on the SEC website